FDA Draws Accusation Of Gender Bias Against FSD Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Some commentators raised concerns that FDA was holding patient-reported outcomes for female sexual dysfunction to a higher standard than similar tools for erectile dysfunction.